Iovance shares hammered on TIL therapy filing delay — although analysts aren't as bothered
Iovance won’t be able to file for its first-ever approval by the end of this year after all.
At issue is the potency assays Iovance …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
